Hookipa Pharma
New York
About Hookipa Pharma
Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms. Hookipa´s TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers. Hookipa has completed the active phase of a Phase 1 trial of a Vaxwave®-based vaccine against cytomegalovirus (CMV) and is finalizing clinical development plans for TheraT® in Human Papilloma Virus (HPV)- related head and neck cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $288.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2023)
- Ticker: nasdaq:HOOK
- Website: hookipapharma.com
- Phone: +43 1 890 63 60
Industries & Categories
Biotechnology, Clinical Trials, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/hookipa-pharma-184144 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.